Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Fresh off Everest’s Hong Kong debut, CBC planning IPO for newly merged portfolio companies

AffaMed, EverInsight will focus on ophthalmology, neurology and psychiatry drugs 

By Amanda Micklus, Senior Biopharma Analyst
October 16, 2020 1:32 AM UTC

Two newly merged companies backed by CBC are already looking ahead to an IPO, a week after a high-profile debut by another of the Asian investment firm’s portfolio companies.

The combination of AffaMed Therapeutics (Shanghai) Co. Ltd. and EverInsight Therapeutics, both of which launched last year, brings together programs in ophthalmology, neurology and psychiatry for the Chinese market as well as rights to an array of biosimilars. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Affamed Therapeutics (Shanghai) Co. Ltd.